BC
TGTX icon

Brookfield Corp’s TG Therapeutics TGTX Stock Holding History

Brookfield Corp’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-123,193
Closed -$3.06M – 491
2023
Q2 		$3.06M Sell
123,193
-375,098
-75% -$9.69M 0.01% 361
2023
Q1 		$7.49M Buy
498,291
+242,842
+95% +$3.69M 0.03% 226
2022
Q4 		$3.02M Sell
255,449
-42,394
-14% -$308K 0.01% 340
2022
Q3 		$1.76M Buy
297,843
+67,153
+29% +$440K 0.01% 476
2022
Q2 		$980K Buy
230,690
+46,897
+26% +$293K ﹤0.01% 506
2022
Q1 		$1.75M Buy
183,793
+115,484
+169% +$1.34M 0.01% 418
2021
Q4 		$1.3M Buy
68,309
+40,980
+150% +$1.06M 0.01% 400
2021
Q3 		$910K Buy
27,329
+8,880
+48% +$275K ﹤0.01% 433
2021
Q2 		$716K Buy
+18,449
New +$724K ﹤0.01% 492

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $758M AUM 124.8% 1-Year Est. Return